Open an account

Resmed

RMD · NYSE

$245.50+$5.73 (+2.39%)TodayMarket closed ·
Prev close $239.77

About RMD

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. The company is headquartered in San Diego, California and currently employs 10,600 full-time employees. The Company, through its subsidiaries, in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. Its segments include Sleep and Breathing Health segment and the Residential Care Software segment. The company also operates a Software as a Service (SaaS) business in the United States and Germany that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. Its products and solutions are designed to improve patients' quality of life and reduce the impact of chronic disease. Its cloud-based digital health software applications, along with its devices, are designed to provide connected care.

Employees
10,600
Headquarters
San Diego, California
Listed
Jun 1, 1995
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
resmed.com

RMD key statistics

Market cap
34.53B
Price-earnings ratio
22.99
Dividend yield
1.01%
Average volume
1.07M
Volume
1.25M
Open price
$242.63
High today
$246.48
Low today
$240.50
52 Week high
$277.67
52 Week low
$180.27

Resmed (RMD) at a glance

Resmed (RMD) last traded at $245.50, with a market cap of 34.53B, a price-to-earnings ratio of 22.99 and a dividend yield of 1.01%.

Today the stock has traded between $240.50 and $246.48. The current price is 2.1% above the day's low and 0.4% below its high.

Volume so far is 1.25M shares, in line with the average of 1.07M shares a day.

Over the past year Resmed has ranged from $180.27 to $277.67, and now sits 67% of the way up that range.

Resmed met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported $2.95 per share against an estimate of $2.92.

The average analyst price target is $254.97, 3.9% above the current price, from 14 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

43%of 14 analyst ratings say Buy
  • Buy42.9%
  • Hold57.1%
  • Sell0.0%
Price target · 19 analystsAvg $254.97
Low
$176.75
Now
$245.50
High
$336.00

RMD earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 5.3% on average.

  1. Q4 FY99: reported $0.0375 per share against an estimate of $0.0366
  2. Q1 FY00: reported $0.0388 per share against an estimate of $0.0356
  3. Q2 FY00: reported $0.0425 per share against an estimate of $0.0404
  4. Q3 FY00: reported $0.045 per share against an estimate of $0.0444
  5. Q4 FY00: reported $0.0475 per share against an estimate of $0.0487
  6. Q1 FY01: reported $0.05 per share against an estimate of $0.0429
  7. Q1 FY26: reported $2.86 per share against an estimate of $2.82
  8. Q2 FY26: reported $2.95 per share against an estimate of $2.92

RMD news

  • Press releaseGlobe Newswire

    Resmed Launches AirTouch™ F40 Full Face Fabric CPAP Mask in the U.S.

  • ResMed Q4 2026 Earnings Call Transcript

  • Piero Cingari

    Stock Market Today: S&P 500, Russell 2000 Fall as 30-Year Yield Hits 5.7%

  • Press releaseGlobe Newswire

    Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD

  • Press releaseGlobe Newswire

    Resmed Announces Participation in the 24th Annual Morgan Stanley Global Healthcare Conference

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD

  • Press releaseGlobe Newswire

    23XI Racing NASCAR Driver Tyler Reddick Reveals Sleep Apnea Diagnosis, Teams Up with Resmed to Help Others Recognize the Signs

Similar companies

Companies in the same industry as Resmed

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.